Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials

Giuseppe Saglio • 17 Dec 2018
ASH 2018
Chronic Myeloid Leukemia Leukemia Imatinib

Most of the information regarding the clinical characteristics of chronic myeloid leukemia (CML) patients are derived from clinical trial data, where any patients not fitting the strict inclusion criteria are excluded. Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, highlights the importance of our knowledge of the characteristics of entire CML populations, before introducing the CML Italian Multicenter Observational Study (CML-IT-MOS), which aims to collect the clinical characteristics, hematologic traits and treatment response of non-selected Italian CML patients. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022

Related Videos

2:05
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
Alberto Olaya-Vargas • 15 Apr 2024
14:43
Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi • 3 May 2024
5:20
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol • 19 Apr 2024
4:15
Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals